Decompensated Hepatitis B Trial

This is double-blinded study to evaluate and compare the safety and tolerability of tenofovir disoproxil fumarate, emtricitabine plus tenofovir disoproxzil fumarage, and entecavir in the treatment of chronic hepatitis B subjects decompensated liver disease.

You may be eligible to participate in this study if:

• Plasma HBV DNA ≥ 10³ copies/ml
• Child-Pugh-Turcotte (CPT) score of 7-12
• No prior use of tenofovir DF or entecavir
• Platelet count ≥ 30,000/mm³

For more information, please call the number below.